title: A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.
abstract: The present study investigated the tolerability, safety profile, and anti-obsessional efficacy of sertraline, a selective serotonin reuptake inhibitor, during long-term treatment of patients with obsessive-compulsive disorder (OCD). Fifty-nine OCD patients who had completed a 1 year double-blind, fixed dose study comparing sertraline and placebo subsequently entered a 1-year open extension. Among the 51 patients who had been treated with sertraline during the double-blind phase, the mean total duration of sertraline treatment was 690 days. Only treatment responders who completed the 52-week double-blind treatment phase were permitted to enter the open extension. The higher rate (p < 0.02) of sertraline patients (51 out of 241) than of placebo patients (eight out of 84), who responded to treatment and entered the open-label phase is therefore consistent with the greater mean improvement observed in the sertraline group during double-blind treatment. Placebo responders differed from sertraline responders in that they were less impaired at baseline of the double-blind study [Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) of 18.5 versus 23.4] and they exhibited less improvement during double-blind treatment (-6.1 versus -11.4). In the open-label phase all patients received sertraline at a starting dose of 50 mg once a day, titrated in 50 mg increments to a maximum dose of 200 mg according to clinical response. At end-point the mean Y-BOCS score for all patients decreased by a further 3.6 points. Patients previously treated with placebo showed greater improvement after being switched to sertraline than those who received continued sertraline treatment. Patients who completed the study and received 2 full years of sertraline treatment (n = 38) exhibited a mean improvement of 15.6 points using the Y-BOCS. Sertraline was well tolerated during both the double-blind phase and the open extension, and the incidence of adverse experiences was generally reduced during the second year of treatment. Three patients discontinued open treatment because of adverse experiences. Long-term sertraline treatment did not appear to be associated with the emergence, increased incidence, or increased severity of adverse experiences or clinically significant abnormalities in laboratory tests, vital signs, or the electrocardiogram. The study supports the long-term safety and tolerability of sertraline over a 2-year treatment course and the sustained efficacy of sertraline in patients with OCD.
authors.affiliation: Department of Psychiatry and Human Behavior, Butler Hospital, Providence, Rhode Island 02906, USA.
authors.forename: S
authors.initials: S
authors.lastname: Rasmussen
authors.forename: E
authors.initials: E
authors.lastname: Hackett
authors.forename: E
authors.initials: E
authors.lastname: DuBoff
authors.forename: J
authors.initials: J
authors.lastname: Greist
authors.forename: A
authors.initials: A
authors.lastname: Halaris
authors.forename: L M
authors.initials: LM
authors.lastname: Koran
authors.forename: M
authors.initials: M
authors.lastname: Liebowitz
authors.forename: R B
authors.initials: RB
authors.lastname: Lydiard
authors.forename: S
authors.initials: S
authors.lastname: McElroy
authors.forename: J
authors.initials: J
authors.lastname: Mendels
authors.forename: K
authors.initials: K
authors.lastname: O'Connor
mesh_terms: D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D020280:Sertraline; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced
chemical_list: D015057:1-Naphthylamine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline